Colleen Kelly
Physician Assistant · Altoona, PANPI 1922481498
Payments from drug & device makers
Across 102 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$570
- Lilly USA, LLC$236
- GSK$166
- Pfizer$125
- Abbott$69
- Axsome Therapeutics, Inc.$68
- plus $569 from 17 others
What the payments were for
- Food & beverage$1,803100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $570 |
| Lilly USA, LLC | 16 | $236 |
| GSK | 11 | $166 |
| Pfizer | 7 | $125 |
| Abbott | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Novo Nordisk | 4 | $62 |
| Tactile Systems Technology Inc | 2 | $58 |
| Exact Sciences | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Merck | 3 | $45 |
| Amgen | 3 | $41 |
| Gilead | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Johnson & Johnson | 2 | $26 |
| Biogen | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Cequr Corporation | 1 | $12 |
How this compares
$1,803 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $37,699 |
| TrulicityDulaglutide | 26 | $26,092 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $15,483 |
| EliquisApixaban | 19 | $13,734 |
| OzempicSemaglutide | 11 | $11,529 |
| Repatha SyringeEvolocumab | 11 | $5,670 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,461 |
| Omega-3 Acid Ethyl Esters | 28 | $1,347 |
| Pantoprazole Sodium | 42 | $847 |
| Atorvastatin Calcium | 65 | $828 |
| Duloxetine Hcl | 21 | $665 |
| Levothyroxine Sodium | 52 | $626 |
| Tolterodine Tartrate | 11 | $371 |
| Rosuvastatin Calcium | 23 | $348 |
| Metformin Hcl | 38 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $13 | $37,69939 claims |
| Lilly USA, LLCTrulicity | $236 | $26,09226 claims |
| GSKTrelegy Ellipta | $166 | $15,48321 claims |
| PfizerEliquis | $125 | $13,73419 claims |
| Novo NordiskOzempic | $62 | $11,52911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Altoona
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.